Pharmaceutical formulations comprising cabazitaxel solubilizer tocopherol polyethylene glycol succinate (TPGSF) one or more hydrotropes optionally one or more agents having a pK of about 3 to about.6 and optionally one or more antioxidlzing agents wherein the formulations are substantially free of polysorbat.es and polyethoxylated castor oil The solubilizer may comprise glycofuroi or ethanol. Pharmaceutical formulations may alternatively comprise cabazitaxel solubilizer optionally one or more agents having a pK of about 3 to about 6 and optionally one or more antioxidizing agents wherein the formulations are substantially free of poiysorbates and polyethoxylated castor oil these formulations may be combined with a diluent which comprises TPGS and one or more hydrotropes. Methods of administering the cabazitaxel formulations include combining the formulations with an infusion solution.
